ReP USP - Resultado da busca

Artigo de periodico
Efficacy and safety of Ixekizumab vs. low-dose IL-2 vs. Colchicine vs. standard of care in the treatment of patients hospitalized with moderate-to-critical COVID-19: A pilot randomized clinical trial (STRUCK: Survival Trial Using Cytokine Inhibitors) (2023)
Bonifácio, Lívia Pimenta ; Ramacciotti, Eduardo ; Agati, Leandro Barile ; Vilar, Fernando Crivelenti; Silva, Anna Christina Tojal da; Louzada Junior, Paulo; Fonseca, Benedito Antonio Lopes da; Souza, Hayala Cristina Cavenague de; Oliveira, Caroline Candida Carvalho de; Aguiar, Valeria Cristina Resende; Kallas, Esper Georges ; Rodrigues, Fernando Bellíssimo
Fonte: Revista da sociedade brasileira de medicina tropical. Unidades: FMRP, FM
Assuntos: COVID-19, PACIENTES INTERNADOS, PANDEMIAS, BRASIL
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BONIFÁCIO, Lívia Pimenta et al. Efficacy and safety of Ixekizumab vs. low-dose IL-2 vs. Colchicine vs. standard of care in the treatment of patients hospitalized with moderate-to-critical COVID-19: A pilot randomized clinical trial (STRUCK: Survival Trial Using Cytokine Inhibitors). Revista da sociedade brasileira de medicina tropical, v. 56, 2023Tradução . . Disponível em: https://observatorio.fm.usp.br/handle/OPI/54695. Acesso em: 16 maio 2024.
APA
Bonifácio, L. P., Ramacciotti, E., Agati, L. B., Vilar, F. C., Silva, A. C. T. da, Louzada Junior, P., et al. (2023). Efficacy and safety of Ixekizumab vs. low-dose IL-2 vs. Colchicine vs. standard of care in the treatment of patients hospitalized with moderate-to-critical COVID-19: A pilot randomized clinical trial (STRUCK: Survival Trial Using Cytokine Inhibitors). Revista da sociedade brasileira de medicina tropical, 56. doi:10.1590/0037-8682-0565-2022
NLM
Bonifácio LP, Ramacciotti E, Agati LB, Vilar FC, Silva ACT da, Louzada Junior P, Fonseca BAL da, Souza HCC de, Oliveira CCC de, Aguiar VCR, Kallas EG, Rodrigues FB. Efficacy and safety of Ixekizumab vs. low-dose IL-2 vs. Colchicine vs. standard of care in the treatment of patients hospitalized with moderate-to-critical COVID-19: A pilot randomized clinical trial (STRUCK: Survival Trial Using Cytokine Inhibitors) [Internet]. Revista da sociedade brasileira de medicina tropical. 2023 ; 56[citado 2024 maio 16 ] Available from: https://observatorio.fm.usp.br/handle/OPI/54695
Vancouver
Bonifácio LP, Ramacciotti E, Agati LB, Vilar FC, Silva ACT da, Louzada Junior P, Fonseca BAL da, Souza HCC de, Oliveira CCC de, Aguiar VCR, Kallas EG, Rodrigues FB. Efficacy and safety of Ixekizumab vs. low-dose IL-2 vs. Colchicine vs. standard of care in the treatment of patients hospitalized with moderate-to-critical COVID-19: A pilot randomized clinical trial (STRUCK: Survival Trial Using Cytokine Inhibitors) [Internet]. Revista da sociedade brasileira de medicina tropical. 2023 ; 56[citado 2024 maio 16 ] Available from: https://observatorio.fm.usp.br/handle/OPI/54695
Artigo de periodico
Treatment of severe COVID-19 patients with either low- or high-volume of convalescent plasma versus standard of care: A multicenter Bayesian randomized open-label clinical trial (COOP-COVID-19-MCTI) (2022)
Song, Alice Tung Wan ; Rocha, Vanderson Geraldo ; Mendrone Júnior, Alfredo ; Rodrigues, Rodrigo do Tocantins Calado de Saloma ; Santis, Gil Cunha De ; Benites, Bruno D. ; Lima, Carolina Costa ; Vargas, Taiani ; Marques, Leonardo da Silva ; Fernandes, Juliana C. ; Breda, Felipe C.; Wendel, Silvano ; Fachini, Roberta; Rizzo, Luiz V. ; Kutner, José Mauro ; Silva, Vivian Helena Iida Avelino da ; Machado, Rafael Rahal Guaragna ; Durigon, Edison Luiz ; Chevret, Sylvie ; Kallas, Esper Georges
Fonte: Lancet Regional Health. Americas. Unidades: FM, FMRP, ICB
Assuntos: MICROBIOLOGIA, COVID-19, ENSAIO CLÍNICO CONTROLADO RANDOMIZADO, PLASMA, SANGUE
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SONG, Alice Tung Wan et al. Treatment of severe COVID-19 patients with either low- or high-volume of convalescent plasma versus standard of care: A multicenter Bayesian randomized open-label clinical trial (COOP-COVID-19-MCTI). Lancet Regional Health. Americas, v. 10, p. 1-10, 2022Tradução . . Disponível em: https://doi.org/10.1016/j.lana.2022.100216. Acesso em: 16 maio 2024.
APA
Song, A. T. W., Rocha, V. G., Mendrone Júnior, A., Rodrigues, R. do T. C. de S., Santis, G. C. D., Benites, B. D., et al. (2022). Treatment of severe COVID-19 patients with either low- or high-volume of convalescent plasma versus standard of care: A multicenter Bayesian randomized open-label clinical trial (COOP-COVID-19-MCTI). Lancet Regional Health. Americas, 10, 1-10. doi:10.1016/j.lana.2022.100216
NLM
Song ATW, Rocha VG, Mendrone Júnior A, Rodrigues R do TC de S, Santis GCD, Benites BD, Lima CC, Vargas T, Marques L da S, Fernandes JC, Breda FC, Wendel S, Fachini R, Rizzo LV, Kutner JM, Silva VHIA da, Machado RRG, Durigon EL, Chevret S, Kallas EG. Treatment of severe COVID-19 patients with either low- or high-volume of convalescent plasma versus standard of care: A multicenter Bayesian randomized open-label clinical trial (COOP-COVID-19-MCTI) [Internet]. Lancet Regional Health. Americas. 2022 ; 10 1-10.[citado 2024 maio 16 ] Available from: https://doi.org/10.1016/j.lana.2022.100216
Vancouver
Song ATW, Rocha VG, Mendrone Júnior A, Rodrigues R do TC de S, Santis GCD, Benites BD, Lima CC, Vargas T, Marques L da S, Fernandes JC, Breda FC, Wendel S, Fachini R, Rizzo LV, Kutner JM, Silva VHIA da, Machado RRG, Durigon EL, Chevret S, Kallas EG. Treatment of severe COVID-19 patients with either low- or high-volume of convalescent plasma versus standard of care: A multicenter Bayesian randomized open-label clinical trial (COOP-COVID-19-MCTI) [Internet]. Lancet Regional Health. Americas. 2022 ; 10 1-10.[citado 2024 maio 16 ] Available from: https://doi.org/10.1016/j.lana.2022.100216
Artigo de periodico
Predicting the outcome for COVID-19 patients by applying time series classification to electronic health records (2022)
Rodrigues, Davi Silva ; Nastri, Ana Catharina de Seixas Santos ; Magri, Marcello M.; Oliveira, Maura Salaroli de ; Sabino, Ester Cerdeira ; Figueiredo, Pedro H. M. F.; Levin, Anna Sara ; Freire, Maristela P. ; Harima, Leila; Nunes, Fátima L. S.; Ferreira, João Eduardo ; Busatto, Geraldo ; Bonfa, Eloisa Silva Dutra de Oliveira ; Utiyama, Edivaldo Massazo ; Segurado, Aluisio Augusto Cotrim ; Perondi, Beatriz ; Morais, Anna M.; Montal, Amanda ; Fusco, Solange ; Fregonesi, Marjorie; Rocha, Marcelo; Marcílio, Izabel ; Rios, Izabel C; Kawano, Fabiane Y. O.; de Jesus, M. Amelia; Kallas, Esper Georges ; Marmo, Carolina; Tanaka, Clarice ; Souza, Heraldo Possolo de ; Marchini, Julio Flavio ; Carvalho, Carlos; Ferreira, Juliana C.; Guimarães, Thais ; Lazari, Carolina S.; Duarte, Alberto José da Silva; Francisco, M. Cristina P. B.; Costa, Sílvia Figueiredo
Fonte: BMC Medical Informatics and Decision Making. Unidades: FM, EACH, IME, FMRP
Assuntos: COVID-19, SINAIS VITAIS, ANÁLISE DE SÉRIES TEMPORAIS, COMPUTAÇÃO APLICADA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
RODRIGUES, Davi Silva et al. Predicting the outcome for COVID-19 patients by applying time series classification to electronic health records. BMC Medical Informatics and Decision Making, v. 22, n. artigo 187, 2022Tradução . . Disponível em: https://doi.org/10.1186/s12911-022-01931-5. Acesso em: 16 maio 2024.
APA
Rodrigues, D. S., Nastri, A. C. de S. S., Magri, M. M., Oliveira, M. S. de, Sabino, E. C., Figueiredo, P. H. M. F., et al. (2022). Predicting the outcome for COVID-19 patients by applying time series classification to electronic health records. BMC Medical Informatics and Decision Making, 22( artigo 187). doi:10.1186/s12911-022-01931-5
NLM
Rodrigues DS, Nastri AC de SS, Magri MM, Oliveira MS de, Sabino EC, Figueiredo PHMF, Levin AS, Freire MP, Harima L, Nunes FLS, Ferreira JE, Busatto G, Bonfa ESD de O, Utiyama EM, Segurado AAC, Perondi B, Morais AM, Montal A, Fusco S, Fregonesi M, Rocha M, Marcílio I, Rios IC, Kawano FYO, de Jesus MA, Kallas EG, Marmo C, Tanaka C, Souza HP de, Marchini JF, Carvalho C, Ferreira JC, Guimarães T, Lazari CS, Duarte AJ da S, Francisco MCPB, Costa SF. Predicting the outcome for COVID-19 patients by applying time series classification to electronic health records [Internet]. BMC Medical Informatics and Decision Making. 2022 ; 22( artigo 187):[citado 2024 maio 16 ] Available from: https://doi.org/10.1186/s12911-022-01931-5
Vancouver
Rodrigues DS, Nastri AC de SS, Magri MM, Oliveira MS de, Sabino EC, Figueiredo PHMF, Levin AS, Freire MP, Harima L, Nunes FLS, Ferreira JE, Busatto G, Bonfa ESD de O, Utiyama EM, Segurado AAC, Perondi B, Morais AM, Montal A, Fusco S, Fregonesi M, Rocha M, Marcílio I, Rios IC, Kawano FYO, de Jesus MA, Kallas EG, Marmo C, Tanaka C, Souza HP de, Marchini JF, Carvalho C, Ferreira JC, Guimarães T, Lazari CS, Duarte AJ da S, Francisco MCPB, Costa SF. Predicting the outcome for COVID-19 patients by applying time series classification to electronic health records [Internet]. BMC Medical Informatics and Decision Making. 2022 ; 22( artigo 187):[citado 2024 maio 16 ] Available from: https://doi.org/10.1186/s12911-022-01931-5
Trabalho de evento-resumo periodico
Efficacy of ixekizumab vs. IL-2 vs. colchicine vs. standard of care for the treatment of hospitalized patients with COVID-19: preliminary results of a randomized clinical trial (struck: survival trial using cytokine inhibitors) (2021)
Bonifacio, L.; Ramacciotti, E.; Agati, L.; Vilar, F.; Tojal, A.; Souza, H.; Louzada Júnior, Paulo; Fonseca, Benedito Antonio Lopes da; Lopes, R.; Kallas, Esper Georges ; Bellíssimo-Rodrigues, Fernando
Fonte: Antimicrobial Resistance & Infection Control. Nome do evento: International Conference on Prevention & Infection Control (ICPIC 2021). Unidades: FMRP, FM
Assuntos: COVID-19, PACIENTES INTERNADOS, ESTUDOS MULTICÊNTRICOS, ESTUDOS PROSPECTIVOS, CITOCINAS, ENSAIO CLÍNICO CONTROLADO RANDOMIZADO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BONIFACIO, L. et al. Efficacy of ixekizumab vs. IL-2 vs. colchicine vs. standard of care for the treatment of hospitalized patients with COVID-19: preliminary results of a randomized clinical trial (struck: survival trial using cytokine inhibitors). Antimicrobial Resistance & Infection Control. London: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. Disponível em: https://aricjournal.biomedcentral.com/track/pdf/10.1186/s13756-021-00974-z.pdf. Acesso em: 16 maio 2024. , 2021
APA
Bonifacio, L., Ramacciotti, E., Agati, L., Vilar, F., Tojal, A., Souza, H., et al. (2021). Efficacy of ixekizumab vs. IL-2 vs. colchicine vs. standard of care for the treatment of hospitalized patients with COVID-19: preliminary results of a randomized clinical trial (struck: survival trial using cytokine inhibitors). Antimicrobial Resistance & Infection Control. London: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. Recuperado de https://aricjournal.biomedcentral.com/track/pdf/10.1186/s13756-021-00974-z.pdf
NLM
Bonifacio L, Ramacciotti E, Agati L, Vilar F, Tojal A, Souza H, Louzada Júnior P, Fonseca BAL da, Lopes R, Kallas EG, Bellíssimo-Rodrigues F. Efficacy of ixekizumab vs. IL-2 vs. colchicine vs. standard of care for the treatment of hospitalized patients with COVID-19: preliminary results of a randomized clinical trial (struck: survival trial using cytokine inhibitors) [Internet]. Antimicrobial Resistance & Infection Control. 2021 ; 10 61.[citado 2024 maio 16 ] Available from: https://aricjournal.biomedcentral.com/track/pdf/10.1186/s13756-021-00974-z.pdf
Vancouver
Bonifacio L, Ramacciotti E, Agati L, Vilar F, Tojal A, Souza H, Louzada Júnior P, Fonseca BAL da, Lopes R, Kallas EG, Bellíssimo-Rodrigues F. Efficacy of ixekizumab vs. IL-2 vs. colchicine vs. standard of care for the treatment of hospitalized patients with COVID-19: preliminary results of a randomized clinical trial (struck: survival trial using cytokine inhibitors) [Internet]. Antimicrobial Resistance & Infection Control. 2021 ; 10 61.[citado 2024 maio 16 ] Available from: https://aricjournal.biomedcentral.com/track/pdf/10.1186/s13756-021-00974-z.pdf

Unidades USP

ReP

Filtros

Departamento

Autores

Autores USP

Assuntos

Afiliação dos autores externos não normalizada